Some insurers have added the carcinoembryonic antigen (CEA) blood test to the laboratory screening profile for Life and Health insurance applications, and some of our U.S. clients have asked for advice on whether to adopt this test.
Is science fiction becoming science fact? Liquid biopsies are a new class of blood- (or other bodily fluid-based) tests that can reveal direct evidence of cancer and are far less invasive than traditional biopsies. RGA's Dr. Daniel Zimmerman explores linkages between advances in genetics and this new technology. He also investigates limitations, potential mortality and morbidity impacts, and insurance implications.
Trick or Treat: How Smarter Segmentation and Data Use Can Help Insurers Win Policyholders and Avoid Ghoulish Risks
For some, there’s no spookier scenario than blood work and cumbersome forms to obtain insurance coverage. But as Neil Parkin of RGA South Africa explains, emerging risk segmentation techniques, combined with smarter use of data, could help ease these fears.
If the insurance industry is informed about medical advancements, a huge advantage arises for future underwriting with regards to calculating ratings for specific diseases and also creating digital application forms with simplified underwriting.
We began 2018 with some promising news on cancer: A simple blood test can now detect disease in eight common sites. Called the CancerSEEK test, it was developed at the Johns Hopkins Kimmel Cancer Center, and may herald a new age in cancer medicine
In recent years, we have learned a great deal about the insurability implications of two common tests: total bilirubin and a component of the CBC called the red blood cell distribution index (RDW).